[Form 4] Metropolitan Bank Holding Corp. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 overview: On 22 Jul 2025, Maiken Keson-Brookes, Chief Legal Officer & Secretary of Mural Oncology plc (MURA), sold 2,572 ordinary shares at a weighted-average price of $2.48 (price band $2.46-$2.51). The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on 20 Sep 2024.

Following the transaction, the insider directly owns 68,834 shares, which include 62,203 unvested RSUs. No derivative securities were reported and no other insiders participated. The filing indicates direct ownership status and contains the standard acknowledgements and signatures required under Section 16.

Insights

Insider Transaction Analyst

TL;DR: Small 10b5-1 sale; negligible impact on ownership, neutral signal.

The disposal represents roughly 3.7 % of Keson-Brookes’ reported holdings (68,834 post-sale). Because it was executed under a pre-established 10b5-1 plan, the transaction is generally viewed as routine and reduces signalling risk. The insider still retains a substantial position, including a large block of unvested RSUs, implying continued alignment with shareholder interests. No options, warrants, or other derivatives were exercised or disposed. Given the limited size and pre-planned nature, market impact should be minimal.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Lublin Scott

(Last) (First) (Middle)

99 PARK AVENUE

(Street)

NEW YORK NY 10016

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Metropolitan Bank Holding Corp. [ MCB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and Chief Lending Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/21/2025		S(1)		3,424	D	$78.3396(2)	47,755(3)(4)(5)(6)	D
Common Stock	07/21/2025		S(1)		1,420	D	$79.2413(7)	46,335(3)(4)(5)(6)	D
Common Stock	07/21/2025		S(1)		156	D	$79.904(8)	46,179(3)(4)(5)(6)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person on March 18, 2025.

2. The $78.3396 price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.7640 to $78.7610, inclusive. The Reporting Person undertakes to provide to Metropolitan Bank Holding Corp., any security holder of Metropolitan Bank Holding Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 2.

3. Includes restricted stock units granted on March 1, 2023 that vest at a rate of 33.3% per year commencing on March 1, 2024.

4. Includes restricted stock units granted on March 1, 2024 that vest at a rate of 33.3% per year commencing on March 1, 2025.

5. Includes restricted stock units granted on March 1, 2025 that vest at a rate of 33.3% per year commencing on March 1, 2026.

6. Includes restricted stock units granted on May 30, 2024, subject to certain performance criteria, that vest at a rate of 33.3% per year commencing on June 1, 2025. The remaining restricted stock units of this award will vest 1/3 on each of February 28, 2026 and 2027.

7. The $79.2413 price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.7667 to $79.7548, inclusive. The Reporting Person undertakes to provide to Metropolitan Bank Holding Corp., any security holder of Metropolitan Bank Holding Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 7.

8. The $79.9040 price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.7921 to $80.0300, inclusive. The Reporting Person undertakes to provide to Metropolitan Bank Holding Corp., any security holder of Metropolitan Bank Holding Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote 8.

	/s/ Zachary Levine, Attorney-in-Fact	07/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many MURA shares did the officer sell?

The Form 4 reports a sale of 2,572 ordinary shares on 22 Jul 2025.

At what price were the shares sold?

Shares were sold at a weighted-average price of $2.48, with individual trades between $2.46 and $2.51.

Does the officer still hold MURA shares after the sale?

Yes. Post-transaction, the officer directly owns 68,834 shares, including 62,203 unvested RSUs.

Was the sale part of a 10b5-1 trading plan?

Yes. The filing states the transaction was executed under a Rule 10b5-1 plan adopted 20 Sep 2024.

Were any derivative securities involved?

No derivative securities were acquired or disposed of in this filing.

Who is the reporting person in this Form 4?

Maiken Keson-Brookes, Chief Legal Officer and Secretary of Mural Oncology plc.